Announced

Athenex to acquire Kuur Therapeutics from Schroder for $185m.

Synopsis

Athenex, a biopharmaceutical company, agreed to acquire Kuur Therapeutics, developer of cell immunotherapies for the treatment of solid and hematological malignancies, from Schroder, a closed-ended investment company, for $185m. “Kuur’s innovative technology, combined with our TCR program, could propel us into a leadership position in cell therapy. This platform also has the potential to provide synergies with other assets in our pipeline,” Johnson Lau, Athenex CEO.

Principals

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US